October 12, 2022
On October 12, ASBM Immediate Past Chair Madelaine Feldman, MD, FACR participated in a forum held by STAT, entitled “Biosimilars’ Meteoric Moment”. The forum focused on the long-awaited arrival of multiple adalimumab biosimilars in 2023 and asked experts from a variety of fields to speculate on what 2023 holds for the biosimilars market. Speakers included: Madelaine A. […]
October 10, 2022
As reported in Generics Bulletin October 10th, Dr. Sarah McMullen, India country director for the US Food and Drug Administration underscored that there’s no real distinction in the standards to determine the safety or efficacy for both biosimilars and interchangeable biosimilars, and put forth a “fact check” to dispel the general notion among patients that interchangeables are […]
October 10, 2022
As reported in Generics Bulletin October 10th, Dr. Sarah McMullen, India country director for the US Food and Drug Administration underscored that there’s no real distinction in the standards to determine the safety or efficacy for both biosimilars and interchangeable biosimilars, and put forth a “fact check” to dispel the general notion among patients that interchangeables are […]
October 6, 2022
AMERICAN ACADEMY OF OPHTHALMOLOGY“‘ POLICY STATEMENT The Use of Biosimilars in Ophthalmic Practice Background Congress, through the Biologics Price Competition and Innovation Act (BPCI Act) of 2009, created an abbreviated approval pathway for biological products that are demonstrated to be biosimilar to or interchangeable with a Food and Drug Administration (FDA)-approved biological product.1 […]
October 6, 2022
AMERICAN ACADEMY OF OPHTHALMOLOGY“‘ POLICY STATEMENT The Use of Biosimilars in Ophthalmic Practice Background Congress, through the Biologics Price Competition and Innovation Act (BPCI Act) of 2009, created an abbreviated approval pathway for biological products that are demonstrated to be biosimilar to or interchangeable with a Food and Drug Administration (FDA)-approved biological product.1 […]
October 6, 2022
On October 4-5, 2022 ASBM Advisory Board Chair Philip Schneider participated in the World Drug Safety Congress Americas 2022, held in Boston, MA. The annual pharmacovigilance (PV) conference bills itself as “the largest commercial gathering of PV professionals in the world. During the two-day conference, Prof. Schneider chaired both the Global PV Track and Advanced Therapies […]
October 6, 2022
On October 4-5, 2022 ASBM Advisory Board Chair Philip Schneider participated in the World Drug Safety Congress Americas 2022, held in Boston, MA. The annual pharmacovigilance (PV) conference bills itself as “the largest commercial gathering of PV professionals in the world. During the two-day conference, Prof. Schneider chaired both the Global PV Track and Advanced Therapies […]
September 4, 2022
In August, ASBM recorded two new entries in its ongoing continuing education (CE) series in partnership with the Ohio State University College of Pharmacy. These represent part 4 and 6 of the 7-part series covering a wide range of biosimilar policy issues. View the previous three entries here. Module 4: Physician Perspectives on Biosimilars In this module, […]
September 3, 2022
On August 31st, several ASBM representatives joined Tiffany Westrich-Robertson, CEO of the International Foundation for Autoimmune & Autoinflammatory Diseases, to record an episode of the AI Arthritis Voices 360 podcast. The episode discussed examined policy issues surrounding biosimilars and how these affect patients. ASBM was represented in the discussion by Executive Director Michael Reilly; Chairman Ralph McKibbin, […]
June 24, 2022
On June 20th, ASBM Chairman Ralph McKibbin, MD, FACP, FACG, AGAF presented a poster at the DIA Global Annual Meeting 2022 in Chicago, IL. The poster was entitled “U.S. Physician Perspectives on Biosimilar Substitution and Reimbursement Practices” and featured results from ASBM’s 2021 survey of 401 U.S. physicians. Among its key findings: Nearly all physicians surveyed expressed […]
